Methodology to Incorporate Biologically Effective Dose and Equivalent Uniform Dose in Patient-Specific 3-Dimensional Dosimetry for Non-Hodgkin Lymphoma Patients Targeted with (131)I-Tositumomab Therapy

Lignende værker

• (131)I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
  af: Dewaraja, Yuni K., et al.
  Udgivet: (2010)
• Bio-effect model applied to (131)I radioimmunotherapy of refractory non-Hodgkin’s lymphoma
  af: Roberson, Peter L., et al.
  Udgivet: (2010)
• Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy
  af: Dewaraja, Yuni K., et al.
  Udgivet: (2014)
• Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
  af: Andemariam, Biree, et al.
  Udgivet: (2007)
• Accurate Dosimetry in (131)I Radionuclide Therapy Using Patient-Specific, 3-Dimensional Methods for SPECT Reconstruction and Absorbed Dose Calculation
  af: Dewaraja, Yuni K., et al.
  Udgivet: (2005)